Christophe Peixoto

USPTO Granted Patents = 19 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 8.1

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

Les Laboratoires Servier

patents

1 out of 53

Les Laboratories Servier

patents

4. 1 out of 1

Dart Therapeutics LLC

patent

5. 1 out of 1

Onco3r Therapeutics Bv

patent

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12391679 - Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases (2025-08-19),

2. 12264156 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2025-04-01),

3. 12065443 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2024-08-20),

4. 11718588 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2023-08-08),

5. 11339166 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2022-05-24),

6. 11072611 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2021-07-27),

7. 10941117 - 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2021-03-09),

8. 10829478 - 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis (2020-11-10),

9. 10550100 - 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis (2020-02-04),

10. 10526329 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2020-01-07),

11. 10487060 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2019-11-26),

12. 10125132 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2018-11-13),

13. 9926281 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2018-03-27),

14. 9796719 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2017-10-24),

15. 9670204 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2017-06-06),

Title: The Innovative Contributions of Christophe Peixoto

Introduction: Christophe Peixoto, based in Romainville, France, is a prolific inventor recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 18 patents, Peixoto's work focuses on developing compounds and pharmaceutical compositions aimed at treating various diseases.

Latest Patents: Among Peixoto's latest patents are two notable inventions that disclose compounds categorized under specific formulas. These inventions relate to methods for producing compounds and their use in pharmaceutical compositions for preventing and treating a wide array of diseases. These include inflammatory diseases, autoinflammatory conditions, autoimmune disorders, proliferative and fibrotic diseases, and complications associated with cartilage and bone turnover. Additionally, his inventions address diseases linked to hypersecretion of IL-6, TNFα, and other cytokines, as well as respiratory, endocrine, metabolic, cardiovascular, dermatological diseases, and conditions associated with abnormal angiogenesis through the administration of the compounds he has developed.

Career Highlights: Throughout his career, Christophe Peixoto has worked with esteemed companies in the pharmaceutical industry. Notably, he has been associated with Galapagos NV and Les Laboratoires Servier, where he applied his expertise in drug development and innovation. His work has been integral to advancing therapeutic options in various medical fields.

Collaborations: Peixoto has collaborated with several notable professionals throughout his career, including Nicolas Desroy and Reginald Christophe Xavier Brys. These collaborations have further enriched his research and development efforts, contributing to his successful patent portfolio.

Conclusion: Christophe Peixoto stands out as a leading innovator in the pharmaceutical field. His 18 patents, focusing primarily on the treatment of complex diseases, reflect his commitment to enhancing healthcare through innovative solutions. As he continues his work, Peixoto's contributions will undoubtedly play a crucial role in the future of medicinal chemistry and therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.